MAPT and Alzheimer disease: This supports the usefulness of inflammation (I) biomarkers (such as plasma GFAP) to establish a more accurate diagnosis scheme in the clinic but also provides novel insights into understanding how astrocyte reactivity affects the cortical tau aggregation and cortical thinning in AD.